Why do clinical trials of Xpert® MTB/RIF fail to show an effect on patient relevant outcomes?

Int J Tuberc Lung Dis. 2017 Mar 1;21(3):249-250. doi: 10.5588/ijtld.16.0801.
No abstract available

MeSH terms

  • Antibiotics, Antitubercular / pharmacology
  • Antibiotics, Antitubercular / therapeutic use
  • Clinical Trials as Topic*
  • Humans
  • Mycobacterium tuberculosis / drug effects
  • Mycobacterium tuberculosis / genetics
  • Mycobacterium tuberculosis / isolation & purification*
  • Real-Time Polymerase Chain Reaction
  • Rifampin / pharmacology
  • Rifampin / therapeutic use
  • Treatment Outcome*
  • Tuberculosis, Multidrug-Resistant / diagnosis*
  • Tuberculosis, Multidrug-Resistant / drug therapy
  • Tuberculosis, Multidrug-Resistant / microbiology
  • Tuberculosis, Pulmonary / diagnosis*
  • Tuberculosis, Pulmonary / drug therapy
  • Tuberculosis, Pulmonary / microbiology

Substances

  • Antibiotics, Antitubercular
  • Rifampin